Comparative Pharmacology
Head-to-head clinical analysis: DETROL versus DETROL LA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DETROL versus DETROL LA.
DETROL vs DETROL LA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive muscarinic receptor antagonist, primarily targeting M3 receptors in the bladder, reducing detrusor muscle contractions and increasing bladder capacity.
Tolterodine is a competitive muscarinic receptor antagonist. It blocks acetylcholine binding at muscarinic receptors (M1–M5), reducing detrusor muscle contraction and bladder pressure, thereby increasing bladder capacity and decreasing urinary frequency.
2 mg orally twice daily; may increase to 4 mg daily in divided doses based on response.
4 mg orally once daily; may be reduced to 2 mg once daily based on tolerability.
None Documented
None Documented
Terminal half-life 6.9 hours (range 4-10 hours) for tolterodine; 7.7 hours (range 5-13 hours) for active 5-hydroxymethyl metabolite; prolonged in hepatic impairment (up to 3-fold).
Terminal elimination half-life is approximately 7 hours (range 5-10 hours) for the extended-release formulation, allowing once-daily dosing.
Renal: 77% (as metabolites, <1% unchanged); Fecal: 17%; Biliary: minor.
Approximately 77% eliminated in urine (primarily as metabolites, <1% unchanged) and 17% in feces.
Category C
Category C
Anticholinergic
Anticholinergic